If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

  • Oral drug delivery, bioavailability enhancement and lymphatic drug transport
  • Lipid-based formulation design and assessment
  • Intracellular drug transport pathways and nuclear targeting
  • Nanomedicines, in particular dendrimer-based drug delivery
  • Translation and commercialisation

Monash teaching commitment

  • Biopharmaceutical principles of drug delivery (PAC 4261)
  • Drug delivery system design (PSC 3081)
  • Research project (PAC 3522)

Biography

Chris Porter is Director, Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University, Melbourne and Professor of Pharmaceutics. He completed his undergraduate and graduate studies at the University of Nottingham before moving to Australia in 1992. Subsequently, Chris’ research program has focused on understanding and quantifying drug absorption, distribution and elimination profiles and on developing the models and techniques to probe these interactions. A major interest has been the issues and problems surrounding the absorption of poorly water soluble, highly lipophilic drugs. In particular Chris' programs have explored the use of lipid-modified drugs and lipid based delivery systems to promote drug integration into endogenous lipid transport pathways in order to enhance oral bioavailability and stimulate lymphatic transport. His interests have also expanded into the mechanisms of cellular transport of lipophilic drugs. In parallel Chris has a long standing interest in the potential utility of dendrimers as drug delivery systems. Chris has published more than 220 peer reviewed papers in these areas, attracting >16,000 citations (h-index 70, Google Scholar) and is a Thompson ISI/Clarivate Highly Cited researcher (2015, 2016, 2018). His research programs have attracted ~$17m in funding from government and commercial organisations. He is an inventor on >15 patent families and this IP has been commercialised through three major licencing/assignment deals with Starpharma, PureTech and Lonza. His group continues to collaborate closely with all three organisations to progress the technologies. Chris is a current member of the Editorial Boards of ACS Molecular Pharmaceutics, Pharmaceutical Research, the Journal of Pharmaceutical Sciences and the Journal of Pharmacy and Pharmacology. He is a previous member of the Board of Scientific Advisors of CRS. He is a fellow of the American Association of Pharmaceutical Scientists and the Royal Australian Chemical Institute.

Keywords

  • Intracellular Binding Proteins
  • Lipid-Based Formulation Design
  • Lymphatic Drug Transport
  • Nanomedicines
  • Dendrimer-Based Drug Delivery
  • Oral Drug Delivery
  • Bioavailability Enhancement
  • Polyethylene Glycol
  • Dendrimer
  • Poly L-Lysine
  • Pharmacokinetics
  • Biodistribution

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2003 2021

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology

Davis, T., Boyd, B., Bunnett, N., Caruso, F., Corrie, S. R., Crampin, E., Gooding, J., Johnston, A., Kavallaris, M., Kearnes, M., Kent, S., McGhee, J., Nann, T., Parton, R., Porter, C., Thordarson, P., Thurecht, K., Voelcker, N. H., Whittaker, A., Abbott, N., Alexander, C., Dawson, K., Greguric, I., Haddleton, D., Hawker, C., Lee, D. S., Lewis, J., McLean, K., Stevens, M., Jones-Jayasinghe, N., Thierry, B. & Prestidge, C. A.

Australian Research Council (ARC), Memorial Sloan Kettering Cancer Center, The University of Nottingham (UK), University College Dublin, University of California , University of Warwick, University of Wisconsin-Madison, SungKyunKwan University, Monash University, The University of Melbourne, The University of New South Wales, The University of Queensland , University of South Australia, Australian Nuclear Science and Technology Organisation , CSIRO Materials Science and Engineering (CMSE), Imperial College London

30/06/1429/06/21

Project: Research

Research Output 1982 2019

Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief

Jensen, D. D., Lieu, T., Halls, M. L., Veldhuis, N. A., Imlach, W. L., Mai, Q. N., Poole, D. P., Quach, T., Aurelio, L., Conner, J., Klein Herenbrink, C., Barlow, N., Simpson, J. S., Scanlon, M. J., Graham, B., McCluskey, A., Robinson, P. J., Escriou, V., Nassini, R., Materazzi, S. & 6 othersGeppetti, P., Hicks, G. A., Christie, M. J., Porter, C. J. H., Canals, M. & Bunnett, N. W., 31 May 2017, In : Science Translational Medicine. 9, 392, 15 p., aal3447.

Research output: Contribution to journalArticleResearchpeer-review

Glyceride-mimetic prodrugs incorporating self-immolative spacers promote lymphatic transport, avoid first-pass metabolism, and enhance oral bioavailability

Hu, L., Quach, T., Han, S., Lim, S. F., Yadav, P., Senyschyn, D., Trevaskis, N. L., Simpson, J. S. & Porter, C. J. H., 2016, In : Angewandte Chemie - International Edition. 55, 44, p. 13700 –13705 6 p.

Research output: Contribution to journalArticleResearchpeer-review

From sewer to saviour-targeting the lymphatic system to promote drug exposure and activity

Trevaskis, N., Kaminskas, L. M. & Porter, C. J., 2015, In : Nature Reviews Drug Discovery. 14, 11, p. 781 - 803 23 p.

Research output: Contribution to journalArticleResearchpeer-review

Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission

Yarwood, R. E., Imlach, W. L., Lieu, T., Veldhuis, N. A., Jensen, D. D., Herenbrink, C. K., Aurelio, L., Cai, Z., Christie, M. J., Poole, D. P., Porter, C. J. H., McLean, P., Hicks, G. A., Geppetti, P., Halls, M. L., Canals, M. & Bunnett, N. W., 14 Nov 2017, In : Proceedings of the National Academy of Sciences of the United States of America. 114, 46, p. 12309-12314 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs

Porter, C. J., Trevaskis, N. & Charman, W. N., 2007, In : Nature Reviews Drug Discovery. 6, 14, p. 231 - 248 18 p.

Research output: Contribution to journalArticleResearchpeer-review

Prizes

APSA Medal

Christopher Porter (Recipient), 2017

Prize: Prize (including medals and awards)

Clarivate Analytics Highly Cited

Christopher Porter (Recipient), 2018

Prize: Prize (including medals and awards)

Honourary Doctorate - Uppsala University

Christopher Porter (Recipient), 2018

Prize: Honorary degree

Clarivate Analytics Highly Cited

Christopher Porter (Recipient), 2016

Prize: National/international honour

Thompson ISI Highly Cited

Christopher Porter (Recipient), 2015

Prize: National/international honour

Activities 2002 2014

  • 3 Editorial responsibility
  • 2 Professional association or peak discipline body

Fellow of the American Association of Pharmaceutical Scientists

Christopher Porter (Fellow)
2014 → …

Activity: External Academic EngagementProfessional association or peak discipline body

Fellow of the Royal Australian Chemical Institute

Christopher Porter (Fellow)
2009 → …

Activity: External Academic EngagementProfessional association or peak discipline body

Pharmaceutical Research (Publisher)

Christopher Porter (Editorial board member)
1 Jan 2005 → …

Activity: Publication peer-review and editorial work typesEditorial responsibility

Journal of Pharmaceutical Sciences (Publisher)

Christopher Porter (Editorial board member)
1 Jan 2002 → …

Activity: Publication peer-review and editorial work typesEditorial responsibility

Journal of Pharmacy and Pharmacology (Publisher)

Christopher Porter (Editorial board member)
1 Jan 2002 → …

Activity: Publication peer-review and editorial work typesEditorial responsibility